Welcome to our dedicated page for Royalty Pharma plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
Royalty Pharma has announced key changes to its leadership team, appointing Art McGivern as Executive Vice President, Investments & General Counsel, while promoting George Lloyd to Executive Vice President, Investments & Chief Legal Officer. McGivern joins from Goodwin Procter with extensive experience in transaction structuring in the life sciences sector. Lloyd, who has been with the company since 2011, will oversee the legal team as responsibilities increase due to the complexity of transactions. These changes aim to enhance Royalty Pharma's capacity to navigate its growing transaction pipeline.
Royalty Pharma has partnered with Merck to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor for treating schizophrenia. Royalty Pharma will provide $50 million upfront, with an option for an additional $375 million if Merck proceeds to Phase 3 trials. This unique collaboration showcases Royalty Pharma's commitment to innovative funding solutions and reflects the unmet need for new schizophrenia treatments. The partnership positions Royalty Pharma as a key player in biopharmaceutical funding, enhancing its pipeline of promising therapies.
Royalty Pharma plc (Nasdaq: RPRX) is set to participate in several investor conferences this September. Key dates include Citi’s 17th Annual BioPharma Conference on September 8 at 11:20 a.m. ET, Morgan Stanley’s Global Healthcare Conference on September 12 at 10:30 a.m. ET, and Bank of America’s Healthcare Conference on September 15 at 10:55 a.m. ET. Webcasts will be available on Royalty Pharma’s Events page and archived for thirty days. The company, established in 1996, is the leading buyer of biopharmaceutical royalties, focusing on funding innovation across the industry.
Royalty Pharma (Nasdaq: RPRX) reported strong financial results for Q2 2022, highlighting an 8% increase in net cash from operating activities to $575 million and a 10% rise in Adjusted Cash Receipts to $524 million. The company announced transactions totaling $2.5 billion year-to-date, enhancing its royalty portfolio with significant acquisitions including GSK's Trelegy, while raising its 2022 guidance for Adjusted Cash Receipts to $2,275-$2,350 million. CEO Pablo Legorreta emphasized strong market positioning and growth potential, despite a decline in total revenues by 3% to $536 million.
In the second quarter of 2022, Innoviva reported a 7% increase in royalties to $111.7 million, with significant contributions from GSK's products. However, income from operations fell by 14% to $82.6 million due to Entasis' operating expenses. The company completed the acquisition of Entasis for $42 million and a merger agreement with La Jolla Pharmaceutical for $6.23 per share, enhancing long-term growth prospects. Innoviva sold a 15% stake in Theravance for $282 million, bolstering its cash position to $283.6 million as of June 30, 2022.
The board of directors of Royalty Pharma (RPRX) has declared a third-quarter dividend of $0.19 per Class A ordinary share. This dividend will be paid on September 15, 2022, to shareholders on record by the close of business on August 19, 2022. Royalty Pharma, a leader in biopharmaceutical royalties, supports innovation across the industry and has a portfolio that includes royalties on approximately 35 commercial products, enhancing shareholder value.
Royalty Pharma (Nasdaq: RPRX) announced its second quarter 2022 financial results will be reported on August 4, 2022, before U.S. market open. A conference call and webcast will follow at 8:00 a.m. Eastern Time. Royalty Pharma is the largest biopharmaceutical royalty buyer and a leading funder of innovation in the industry. Its portfolio includes royalties from 35 commercial products, including therapies from AbbVie, Johnson & Johnson, and Biogen. The company partners with various entities to fund clinical trials and product launches.
Innoviva has signed an agreement to sell its 15% stake in Theravance Respiratory Company (TRC) to Royalty Pharma for about $282 million upfront and a potential $50 million milestone payment. As part of the deal, Innoviva will maintain full ownership of TRC's private investments and retain royalty rights for ANORO and RELVAR ELLIPTA. The sale, expected to finalize in July 2022, allows Innoviva to bolster its cash position amid market uncertainties. CEO Pavel Raifeld expressed optimism about maximizing shareholder value through this transaction.
Royalty Pharma (RPRX) announced the acquisition of a royalty interest in TRELEGY ELLIPTA for $1.31 billion, with additional potential payments of up to $300 million based on sales milestones. TRELEGY, marketed by GSK, is a leading therapy for chronic obstructive pulmonary disease (COPD) and asthma, generating $1.68 billion in sales in 2021. This acquisition is expected to add at least $200 million to Royalty Pharma's Adjusted Cash Receipts by 2025, enhancing long-term growth and further diversifying its portfolio.
Theravance Biopharma announced an agreement to sell its 85% interest in GSK's TRELEGY ELLIPTA royalty rights to Royalty Pharma for over $1.5 billion in potential value, including approximately $1.1 billion upfront. The deal aims to enhance shareholder value by eliminating debt and returning capital. Additionally, Royalty Pharma will invest $40 million to advance ampreloxetine development for MSA. Following the transaction, Theravance expects to have $430 million in cash and aims for breakeven cash flow in the second half of 2022.
FAQ
What is the current stock price of Royalty Pharma plc (RPRX)?
What is the market cap of Royalty Pharma plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
